New research highlighted by HCPLive suggests that exhaled breath could become a noninvasive, real-time readout of gut microbiome activity, opening a potential new diagnostic frontier. In studies spanning humans, mice, and in-vitro models, researchers showed that volatile organic compounds (VOCs) detected in breath reflect metabolites produced by gut microbes. In healthy children, breath compounds closely matched the metabolic signatures of microbes found in stool. In germ-free mice, transplanting gut bacteria led to detectable microbial signals in breath—directly linking intestinal microbes to breath chemistry.Notably, breath profiles were also able to predict disease-associated microbes. In children with asthma, breath samples identified the…
Author: Abhay Panchal
The Medical Futurist has released its annual list of the 100 Digital Health and AI Companies of 2026, curated by Bertalan Meskó. Now in its ninth year, the list aims to cut through hype and spotlight companies showing real momentum across healthcare AI, devices, and platforms—without sponsorship or financial ties. What’s new in 2026 Key patterns worth watching
The Medicare Payment Advisory Commission (MedPAC) has voted to acknowledge what many physician groups have warned for years: Medicare physician payments are no longer keeping pace with the cost of running a medical practice. In its January vote, MedPAC backed an additional 0.5% payment update on top of the modest increases already written into law and will forward that recommendation to Congress. While incremental, the move reinforces growing concern that the current payment framework is structurally broken. Why this matters The unresolved debate Last year, MedPAC itself called for a more durable fix: linking physician payment updates to the Medicare…
In a surprisingly funny and philosophical essay, The New York Times writer Sam Anderson reframes the colonoscopy—not as a medical ordeal, but as a strangely blissful, almost spiritual experience. What starts as dread turns into satire and self-reflection: the bowel prep becomes a forced “retreat from modern life,” the procedure itself a brief disappearance into oblivion, and the recovery a gentle reentry into the world—with juice, photos of one’s colon, and a clean bill of health.
Aidoc has received FDA clearance for what it describes as healthcare’s first comprehensive AI triage solution powered by a foundation model, marking a significant shift in how AI is deployed across radiology workflows. The clearance brings 11 newly approved acute indications, combined with three previously cleared ones, into a single body CT triage workflow. Built on Aidoc’s CARE™ foundation model and delivered through its aiOS™ enterprise platform, the solution is designed to surface critical findings earlier—particularly in crowded emergency departments and imaging backlogs, where first-in–first-out reading can delay urgent diagnoses.
NYU Langone Health announced the appointment of Anirban Maitra, MD, a preeminent physician–scientist whose work has widely influenced the field of pancreatic cancer research, as the new director of the Laura and Isaac Perlmutter Cancer Center, an NCI-designated Comprehensive Cancer Center. Before joining NYU Langone, Dr. Maitra served as the inaugural scientific director of the Pancreatic Cancer Research Center at the University of Texas MD Anderson Cancer Center in Houston. Dr. Maitra’s work focused on early detection and biomarker development, two key avenues for effective cancer treatments. After serving in a number of leadership roles at MD Anderson, he was…
The Colorectal Cancer Alliance has launched CLEAR for CRC, a patient-centered initiative designed to close persistent gaps in early biomarker testing for newly diagnosed colorectal cancer—particularly for patients with advanced or metastatic disease. Biomarker testing helps identify a tumor’s molecular profile, guiding treatment selection, eligibility for targeted therapies, and access to clinical trials. Despite its clinical importance, testing remains inconsistently ordered, often delayed until after first-line therapy, or missed entirely—especially in rural and underserved communities. CLEAR for CRC addresses these gaps through three core strategies: The initiative is led by Dr. Erin Siegel, principal investigator of the CLEAR for CRC…
GRAIL has submitted the final module of its FDA Premarket Approval (PMA) application for the Galleri® multi-cancer early detection (MCED) blood test, moving the test one step closer to potential regulatory approval and broader clinical adoption in the U.S. The PMA submission is anchored in data from two of the largest MCED studies to date: the PATHFINDER 2 U.S. registrational study and the NHS-Galleri randomized controlled trial in England. Together, these trials evaluate Galleri’s safety, performance, and real-world diagnostic pathways when used alongside standard cancer screening.
A prospective multicenter study published in Therapeutic Advances in Gastrointestinal Endoscopy evaluated whether colon capsule endoscopy (CCE) could serve as a practical alternative for FIT-positive individuals who are unable or unwilling to undergo colonoscopy within a national colorectal cancer screening program. While CCE demonstrated a high per-patient polyp detection rate (77% for lesions ≥6 mm), real-world feasibility proved limited. More than half of eligible FIT-positive patients were excluded due to comorbidities or contraindications, bowel preparation quality was adequate in fewer than 40% of cases, and only 69% of procedures were complete within battery life. Importantly, most patients still required follow-up…
Stool DNA testing climbed sharply after the pandemic began while colonoscopy and fecal immunochemical test use fell, a study of nearly 25 million privately insured Blue Cross Blue Shield beneficiaries found. The study was published in JAMA Network Open and was led by researchers from New Haven, Conn.-based Yale University and the University of California Los Angeles. They analyzed 24,973,642 commercially insured beneficiaries ages 50-75 from 2017 to 2024. About half were women, and nearly one-third received at least one colorectal cancer screening test during the study period.